HALOZYME THERAPEUTICS, INC. Insider Trading Activity

Halozyme Therapeutics President and CEO Helen Torley, who is also a director, reported receiving new equity awards on February 9, 2026.

Accepted by SEC EDGAR 02/11/2026 - 08:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Halozyme Therapeutics President and CEO Helen Torley, who is also a director, reported receiving new equity awards on February 9, 2026. She was granted an option to purchase 53,847 shares of common stock at an exercise price of $80.48 per share.

Torley also acquired 50,013 restricted stock units, plus multiple performance stock unit (PSU) awards of 19,807, 24,985, and 92,714 units. These PSUs became eligible to vest based on a performance period ending December 31, 2025 and remain subject to ongoing service-based vesting, generally through the third anniversary of each PSU grant date.

Insider Trade Summary

Grant/Award: 241,366 shares

Grant/Award 5 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	53,847	$0.00	$0.00
Grant/Award	Restricted Stock Units	50,013	$0.00	$0.00
Grant/Award	Performance Stock Units	19,807	$0.00	$0.00
Grant/Award	Performance Stock Units	24,985	$0.00	$0.00
Grant/Award	Performance Stock Units	92,714	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 53,847 contracts (Direct); Restricted Stock Units — 50,013 contracts (Direct); Performance Stock Units — 288,285 contracts (Direct)

Footnotes (5)

1. F1. This option vests one-fourth on such date and then 1/48th monthly thereafter.
2. F2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
3. F3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
4. F4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
5. F5. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$80.48	02/09/2026		A		53,847		02/09/2027(1)	02/09/2036	Common Stock	53,847	$0	53,847	D
Restricted Stock Units	$0	02/09/2026		A		50,013		02/09/2027(2)	(2)	Common Stock	50,013	$0	50,013	D
Performance Stock Units	$0	02/09/2026		A		19,807		(3)	(3)	Common Stock	19,807	$0	51,171	D
Performance Stock Units	$0	02/09/2026		A		24,985		(4)	(4)	Common Stock	24,985	$0	144,400	D
Performance Stock Units	$0	02/09/2026		A		92,714		(5)	(5)	Common Stock	92,714	$0	92,714	D

Explanation of Responses:

1. This option vests one-fourth on such date and then 1/48th monthly thereafter.

2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

5. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.